EN DE

Alibaba Health Information Technology Ltd (0241) Fair Value & Analysis

Healthcare · HK · Market cap HK$49.7B (≈ $6.3B) · ISIN BMG0171K1018

What is Alibaba Health Information Technology Ltd really worth?

AH Alibaba Health Information Technology Ltd 0241 · HK
PriceHK$3.14
Fair ValueHK$2.04
Upside−35.0%
Quality64/100

A solid business, but trading 54% above our fair value of HK$2.04.

Watch Alibaba Health Information Technology Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Healthy Growth (revenue 5y +17.2 %/yr)
✓Low debt · generates free cash flow

Risks

!Thin margins · 5.7% net margin
!Mixed vs. peers (6/14)
!Moderate moat 45/100
!Evidence only low, so the estimate is less certain
!Weak on dividend: 26 out of 100
Evidence: Low Range HK$1.55 – HK$2.55

Fair value as of: Aug 20, 2026

From 26 valuation models · updated 16 days ago

Share price −13.0% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price sits above even our optimistic bull case (HK$2.55). The favourable scenario is already priced in.
  • The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
  • Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

HK$24.45 HK$2.61 Fair Value HK$2.04 Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 20, 2026.

How to read this chart

60‑month range HK$2.61 – HK$24.45 · fair‑value band HK$1.55 – HK$2.55 · the HK$3.14 price screens above the HK$2.04 fair value. Dashed = 300-day average. As of Aug 20, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Alibaba Health Information Technology Ltd (0241) currently trades at HK$3.14, while our model-based Fair Value estimate is HK$2.04, implying the stock looks roughly 53.9% overvalued today. The Quality Score stands at 64/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of HK$5.58 per share, and 7 of the 26 models we run sit above the HK$3.14 price. Bear case: the Dividend Discount group reads lowest at HK$0.6500, and 19 of the 26 models stay below the price. Evidence for this calculation is low.

Over the trailing twelve months, Alibaba Health Information Technology Ltd generated revenue of HK$34.3B at a net margin of 5.7%. Revenue grew 7.6% year over year. It earns a return on equity of 11.3%. The balance sheet holds a net cash position of HK$5.7B. Fundamentals as of Aug 20, 2026

Our scenario range runs from HK$1.55 (bear case) to HK$2.55 (bull case); at HK$3.14, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 60% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −35%, 0241 screens richer than that median.

Fair Value models

This estimate rests on fiscal year 2026 figures, and about 5 months have passed since. In that time the company retained roughly HK$0.0516 per share, which is 2.5 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF HK$1.79 HK$2.62 HK$5.24 74
EPV HK$1.09 HK$1.21 HK$1.32 74
Growth DCF HK$1.71 HK$3.04 HK$5.22 73
All 26 models by family
DCF Models
FCF DCF HK$1.79 HK$2.62 HK$5.24 74
Owner Earnings HK$2.28 HK$4.73 HK$9.88 69
5Y Revenue Exit HK$1.47 HK$2.27 HK$3.96 68
5Y EBITDA Exit HK$1.55 HK$2.44 HK$4.19 71
5Y P/E Exit HK$2.25 HK$4.74 HK$8.16 65
10Y Revenue Exit HK$1.54 HK$2.94 HK$3.83 64
10Y EBITDA Exit HK$1.64 HK$3.12 HK$5.67 63
10Y P/E Exit HK$2.15 HK$4.62 HK$8.73 58
Earnings-Based
Graham-Dodd HK$0.8200 HK$5.69 HK$7.99 61
Lynch FV HK$2.94 HK$4.20 HK$5.46 59
PEG = 1.0 HK$2.94 HK$4.20 HK$5.46 55
EPV HK$1.09 HK$1.21 HK$1.32 74
Dividend Discount
Gordon GGM HK$0.3700 HK$0.7700 HK$1.21 64
DDM Multi-Stage HK$0.3700 HK$0.6500 HK$0.8000 65
Multiples
P/E Multiple HK$1.98 HK$2.64 HK$3.30 63
P/S Multiple HK$1.53 HK$2.04 HK$2.55 58
P/B Multiple HK$1.53 HK$2.04 HK$2.55 55
EV/EBIT HK$1.60 HK$2.02 HK$2.43 66
EV/EBITDA HK$1.42 HK$1.77 HK$2.13 67
EV/Revenue HK$1.25 HK$1.63 HK$2.01 54
Asset-Based
NCAV (Graham) HK$0.5500 HK$0.7400 HK$1.10 54
Growth DCF
Growth DCF HK$1.71 HK$3.04 HK$5.22 73
Rev-Margin DCF HK$1.58 HK$2.55 HK$4.57 68
Economic Profit
Residual Income HK$0.9900 HK$1.13 HK$2.11 71
ROIC Compounder HK$1.09 HK$1.38 HK$1.70 70
Growth Earnings
Growth-Adj P/E HK$3.91 HK$5.58 HK$7.25 65

Widest divergence: Growth Earnings (HK$5.58) versus Dividend Discount (HK$0.6500). Highest evidence: FCF DCF (74).

Notify me when 0241 reaches fair value

Put 0241 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 22.0 as of Jul 1, 2026
P/S ratio 1.24 P/E × margin
EPS (TTM) HK$0.1200 price ÷ EPS = P/E 22.0
Dividend yield 1.3% payout 34.1%
Net margin 5.7% FY2026
Return on equity 11.3% TTM
More key figures
Profitability
Return on assets (EBIT) 2.6% avg 5y
Operating margin 1.7% TTM
Growth
Revenue (TTM) HK$34.3B TTM
Revenue growth (YoY) +7.6% 3y avg +8.6%
EPS growth (YoY) +0.7%
Balance sheet & cash flow
Free cash flow HK$1.4B FY2025
Net cash HK$5.7B FY2026

Figures from reported company fundamentals · as of Aug 20, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 64/100

Of which business quality 64 · Market factors (momentum, volatility) 13

Profitability 60
Margins and returns on capital today
Quality Growth 56
Are margins and returns improving?
Cashflow 43
Earnings quality: real cash, not paper profit
Fin. Strength 97
Balance sheet, leverage, solvency risk
Investment 85
Disciplined investing over empire-building
Low Volatility 24
Calm price path (market factor)
Momentum 11
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)
Net Issuance 47
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong.

Full company description

Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, healthcare food, adult and family planning products, and various other health-related products. It also provides medical and healthcare services, including medical checkups, medical consultation, appointment-booking, vaccination, dental and mental care, optometry, and nursing services, as well as traditional chinese medicines. The company provides products and services to business-to-customer and business-to-business customers through offline pharmacy outlets, as well as online stores, such as Tmall, Taobao, Alipay, Ele.me, AMap, DingTalk, Freshippo, and Quark. In addition, it engages in the digital tracking business; asset management; network hospital, software technical services, healthcare related internet information and technical services and research; operation of internet hospitals, as well as Alibaba Health, flagship platform of Alibaba Group for integrated online and offline medical and healthcare resources, providing one-stop healthcare solutions. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited was incorporated in 1998 and is based in Causeway Bay, Hong Kong.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Alibaba Health Information Technology Ltd reported revenue of HK$34.3B in FY2026 versus HK$20.6B in FY2022, a compound +13.6%/yr. Reported net income was HK$1.9B in FY2026.

Growth Quality 85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2026)
HK$34.3B
Latest YoY
+12.0%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+8.6%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+17.2%
Avg. revenue growth/yr (26Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+33.4%
Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.
+36.8% (35.5 + 1.3)
Revenue +13.6%/yr
FY22 HK$20.6B
FY23 HK$26.8B
FY24 HK$27.0B
FY25 HK$30.6B
FY26 HK$34.3B
Net income
FY22 −HK$266M
FY23 HK$536M
FY24 HK$883M
FY25 HK$1.4B
FY26 HK$1.9B

0241 screens 54% overvalued. Compare with JD Health International Inc →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Alibaba Health Information Technology Ltd · Fair Value
HK$2.04 −54%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Alibaba Health Information Technology Ltd Fair Value". https://www.fairvalue-calculator.com/stock/0241

Earlier news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

Peer Group

Pharmaceutical Retailers · 57 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 64 · Top 25%
Fair Value upside −35% · Below median
Return on equity (TTM) 11% · Top 25%
Return on assets 4% · Top 25%
Net margin (TTM) 6% · Top 25%
Operating margin (TTM) 2% · Below median
Revenue growth 8% · Above median
Dividend yield (TTM) 1.3% · Below median

Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper

P/E (TTM) 22.0× · Pricier than median
P/B 2.79× · Pricier than median
P/S (TTM) 1.45× · Pricier than 75% of peers
P/FCF 4.6× · Pricier than 75% of peers
EV/EBITDA 30.4× · Pricier than 75% of peers

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 20
FUTURE38 · sector 19
PAST45 · sector 15
HEALTH100 · sector 98
DIVIDEND26 · sector 63

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 20, 2026).

Stock Price Fair Value vs Fair Value
JD Health International Inc 6618 HK$38.86 HK$33.31 −14%
Yifeng Pharmacy Chain Co 603939 ¥22.90 ¥29.07 +27%
DaShenLin Pharmaceutical Group 603233 ¥18.79 ¥23.86 +27%
MedPlus Health Services Limited MEDPLUS ₹656.80 ₹191.97 −71%
LBX Pharmacy Chain Joint Stock Company 603883 ¥13.44 ¥10.57 −21%
Yixintang Pharmaceutical Group 002727 ¥11.61 ¥9.45 −19%
Anhui Huaren Health Pharmaceutical Co 301408 ¥16.31 ¥10.05 −38%
ShuYu Civilian Pharmacy Corp 301017 ¥13.30 ¥5.91 −56%
Apotea AB APOTEA kr 74.15 kr 46.46 −37%
Luyan Pharma Co 002788 ¥10.96 ¥15.91 +45%

Compare Alibaba Health Information Technology Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Alibaba Health Information Technology Ltd (0241) overvalued or undervalued?
As of Aug 20, 2026, our model estimates a fair value of HK$2.04 versus a price of HK$3.14, about −35% upside (overvalued).
What is the fair value of 0241?
Our model-based fair value for Alibaba Health Information Technology Ltd is HK$2.04 (as of Aug 20, 2026), built from audited fundamentals. The current price: HK$3.14.
What is the quality score of 0241?
Alibaba Health Information Technology Ltd has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Alibaba Health Information Technology Ltd (0241)?
Alibaba Health Information Technology Ltd reported trailing-twelve-month revenue of about HK$34.3B (latest available figure, as of Aug 20, 2026).
What is the net profit margin of 0241?
The net profit margin of Alibaba Health Information Technology Ltd is about 5.7%, meaning it keeps roughly 5.7% of revenue as net income. Based on the latest reported figures.
Does Alibaba Health Information Technology Ltd pay a dividend?
Alibaba Health Information Technology Ltd currently shows a dividend yield of about 1.30% relative to its recent price (as of Aug 20, 2026).
Free · no account needed

Watch Alibaba Health Information Technology Ltd in the live analysis

One click puts Alibaba Health Information Technology Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.